UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


WASHINGTON, D.C.  20549 

 

FORM 8-K



CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934



Date of report (Date of earliest event reported):   January 14, 2008

GENTA INCORPORATED


(Exact Name of Registrant as Specified in Its Charter)


Delaware

(State or Other Jurisdiction of Incorporation)


  
     
     
     
  
  
    0-19635

      (Commission File Number)
     
    33-0326866

      (IRS Employer Identification No.)
  
  
     
     
     
  
  
    200 Connell Drive

Berkeley Heights, NJ

      (Address of Principal Executive Offices) 
     
    07922

      (Zip Code)
  



(908) 286-9800

  (Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)


 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant
under any of the following provisions:





    o
     
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



     


    o
     
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



     


    o
     
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



     


    o
     
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 
 
 
 








Item 8.01 Other Events. 
On January 14, 2008, Genta Incorporated, (the Company), announced that the Food and Drug Administration (FDA) has extended its review of Genta’s appeal of the non-approvable decision for a New Drug Application (NDA) that proposed the use of Genasense® (oblimersen sodium injection) plus chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia. The Company had previously provided guidance that a final decision would be available in the fourth quarter of 2007. Genta now envisions receiving this notification later in the current quarter.
Item 9.01 Financial Statements and Exhibits.


 
        
                        
(d) Exhibits.
  

 


 
        
      
 
 
        
      
Exhibit 

      Number
 
        
      
 
 
        
                        
Description
  
 
        
      
 
 
        
      
99.1
 
        
      
 
 
        
  
Press Release of the Company dated January 14, 2008
  

 
 




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 


 
        
                        
 
 
        
                        
 
 
        
                        
GENTA INCORPORATED
  
 
        
                        
Date:  January 14, 2008  
 
        
                        
 
 
        
                        
By: 
 
        
                        
 
 /s/ RICHARD J. MORAN
  
 
        
                        
 
 
        
                        
 
 
        
                        
 
 
        
                        
Name: Richard J. Moran
  
 
        
                        
 
 
        
                        
 
 
        
                        
 
 
        
      
Title:   Senior Vice President, Chief Financial 

                Officer and Corporate Secretary
  

 
 




EXHIBIT INDEX
 


 
        
      
Exhibit 
 Number
 
        
                        
 
 
        
                        
Description
 
        
      
 
 
        
      
Sequentially 
 Numbered Page
  
 
        
                        
99.1
      
 
 
        
      
 
 
        
                        
Press Release of the Company dated January 14, 2008